H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics (RANI) with a Buy rating and $11 price target The firm believes the company has “three significant value drivers,” its platform technology RaniPill, a recently announced collaboration agreement with Chugai Pharmaceutical for the development of a hemophilia product, and potentially an additional five drug targets, as well as RT-114, an oral GLP-1/GLP-2 dual agonist candidate. It expects data readouts on RT-114 to be the biggest driver of near-term value creation for Rani shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RANI:
- Rani Therapeutics Holdings: Innovative RaniPill Platform and RT-114 Program Drive Buy Rating
- Rani Therapeutics price target raised to $10 from $5 at Maxim
- Why This Penny Biotech Stock Is Still Climbing After a 250% Surge
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Rani Therapeutics Secures New Loan Agreement